BTIG Maintains Buy on Alto Neuroscience, Raises Price Target to $28

Alto Neuroscience, Inc. +0.27%

Alto Neuroscience, Inc.

ANRO

25.82

+0.27%

BTIG analyst Thomas Shrader maintains Alto Neuroscience (NYSE: ANRO) with a Buy and raises the price target from $27 to $28.